Semaglutide (Obesity) — Membership Pricing

Other medications in Diabetes & Metabolism

• Sitagliptin
• Tirzepatide
• Tolvaptan
• Acarbose
• Alogliptin
• Burosumab
• Canagliflozin
• Canagliflozin (Renal)

About Semaglutide (Obesity)

Semaglutide has emerged as a significant medication in the fight against obesity, offering a new pathway for many struggling with weight management. At TheDrugClub, we understand the importance of affordable healthcare. Our members can explore potential savings on semaglutide prescriptions, helping to make this vital treatment more accessible.

Semaglutide, often recognized by its brand names, is a prescription medication approved for chronic weight management in adults. It's typically prescribed as an adjunct to a reduced-calorie diet and increased physical activity. This medication is indicated for individuals with a Body Mass Index (BMI) of 27 kg/m² or greater who also have at least one weight-related comorbid condition (such as high blood pressure, type 2 diabetes, or high cholesterol), or for those with a BMI of 30 kg/m² or greater (classified as obese). It serves as a powerful tool to help patients achieve and maintain significant weight loss.

How Semaglutide Works for Weight Management

Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists. It mimics the action of glucagon-like peptide-1 (GLP-1), a natural hormone produced in the gut that plays a crucial role in appetite regulation and glucose metabolism. When administered, semaglutide activates GLP-1 receptors in the brain, which leads to a reduction in appetite and an increase in feelings of fullness (satiety). Additionally, it

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Semaglutide (Obesity) is approved for (FDA label)

OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. • to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.

Source: Read the full FDA label on DailyMed. Label effective date: July 30, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Semaglutide (Obesity) (FDA label)

WARNING: RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), Nonclinical Toxicology ( 13.1 )] . • OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications ( 4 )] . Counsel patients regarding the potential risk for MTC with the use of OZEMPIC and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with OZEMPIC [see Contraindications ( 4 ), Warnings and Precautions ( 5.1 )] . WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. • In rodents, semaglutide causes thyroid C-cell tumors. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined ( 5.1 , 13.1 ).

Source: FDA prescribing information (DailyMed). Set ID: 42bdd912-2393-44c4-b7e0-47672ca28991. SPL document ID: 4b9bdfa7-1075-45cd-baac-66632beb38df. Label effective date: July 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Semaglutide (Obesity) (FDA label)

Injection: clear, colorless solution available as follows: Single-Patient-Use Pens (with multiple weekly doses) Dose per Injection Total Strength per Total Volume Strength per mL 0.25 mg 0.5 mg 2 mg / 3 mL 0.68 mg/mL 1 mg 4 mg / 3 mL 1.34 mg/mL 2 mg 8 mg / 3 mL 2.68 mg/mL Single-Dose Prefilled Syringes Dose per Injection Total Strength per Total Volume 0.25 mg 0.25 mg / 0.5 mL 0.5 mg 0.5 mg / 0.5 mL 1 mg 1 mg / 0.5 mL • Injection: 2 mg/3 mL (0.68 mg/mL) for 4 doses of 0.25 mg and 2 doses of 0.5 mg or 4 doses of 0.5 mg, 4 mg/3 mL (1.34 mg/mL) for 4 doses of 1 mg, and 8 mg/3 mL (2.68 mg/mL) for 4 doses of 2 mg in single-patient-use pens ( 3 ) • Injection: 0.25 mg, 0.5 mg or 1 mg per 0.5 mL in a single-dose prefilled syringe ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 42bdd912-2393-44c4-b7e0-47672ca28991. SPL document ID: 4b9bdfa7-1075-45cd-baac-66632beb38df. Label effective date: July 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Semaglutide (Obesity) (FDA label)

The following serious adverse reactions are described below or elsewhere in the prescribing information: • Risk of Thyroid C-cell Tumors [see Warnings and Precautions ( 5.1 )] • Acute Pancreatitis [see Warnings and Precautions ( 5.2) ] • Diabetic Retinopathy Complications [see Warnings and Precautions ( 5.3 )] • Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions ( 5.5 )] • Acute Kidney Injury Due to Volume Depletion [see Warnings and Precautions ( 5.6 )] • Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions ( 5.7 )] • Hypersensitivity Reactions [see Warnings and Precautions ( 5.8 )] • Acute Gallbladder Disease [see Warnings and Precautions ( 5.9 )] • Pulmonary Aspiration During General Anesthesia or Deep Sedation [see Warnings and Precautions ( 5.10 )] The most common adverse reactions reported in ≥5% of patients treated with OZEMPIC are: nausea, vomiting, diarrhea, abdominal pain and constipation. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc., at 1-888-693-6742 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 42bdd912-2393-44c4-b7e0-47672ca28991. SPL document ID: 4b9bdfa7-1075-45cd-baac-66632beb38df. Label effective date: July 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Semaglutide (Obesity) (FDA label)

OZEMPIC is contraindicated in patients with: • A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions ( 5.1 )] . • A serious hypersensitivity reaction to semaglutide or to any of the excipients in OZEMPIC. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with OZEMPIC [see Warnings and Precautions ( 5.8 )] . • Personal or family history of MTC or in patients with MEN 2. ( 4 ) • Serious hypersensitivity reaction to semaglutide or any of the excipients in OZEMPIC. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 42bdd912-2393-44c4-b7e0-47672ca28991. SPL document ID: 4b9bdfa7-1075-45cd-baac-66632beb38df. Label effective date: July 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Semaglutide (Obesity) (FDA label)

• Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, including OZEMPIC. Discontinue if pancreatitis is suspected. ( 5.2 ) • Diabetic Retinopathy Complications: Has been reported in a clinical trial. Patients with a history of diabetic retinopathy should be monitored. ( 5.3 ) • Never share an OZEMPIC pen between patients , even if the needle is changed. ( 5.4 ) • Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing dose of insulin secretagogue or insulin may be necessary. ( 5.5 ) • Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion. ( 5.6 ) • Severe Gastrointestinal Adverse Reactions : Use has been associated with gastrointestinal adverse reactions, sometimes severe.

Source: FDA prescribing information (DailyMed). Set ID: 42bdd912-2393-44c4-b7e0-47672ca28991. SPL document ID: 4b9bdfa7-1075-45cd-baac-66632beb38df. Label effective date: July 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Semaglutide (Obesity) (FDA label)

Oral Medications : OZEMPIC delays gastric emptying. May impact absorption of concomitantly administered oral medications. Use with caution. ( 7.2 ) 7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin OZEMPIC stimulates insulin release in the presence of elevated blood glucose concentrations. Patients receiving OZEMPIC in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. When initiating OZEMPIC, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions ( 5.5 ), Adverse Reactions ( 6 )] . 7.2 Oral Medications OZEMPIC causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications.

Source: FDA prescribing information (DailyMed). Set ID: 42bdd912-2393-44c4-b7e0-47672ca28991. SPL document ID: 4b9bdfa7-1075-45cd-baac-66632beb38df. Label effective date: July 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.